Physician profile
Kevin D Rosin
NPI 1184668121
$59,051.12
in general payments reported to CMS, 2019-2025
23 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $850 · 2021: $5,042 · 2022: $15K · 2023: $12K · 2024: $9,367 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,750 · Food and Beverage: $5,997 · Travel and Lodging: $4,541 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,660.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,750.00 |
| Food and Beverage | $5,996.99 |
| Travel and Lodging | $4,541.14 |
| Education | $249.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $45,636.74 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $6,902.53 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $1,251.38 | 2019-2025 | Tryptyr, Dailies Total1, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $1,042.98 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $859.71 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $488.83 | 2023-2025 | Oxervate |
| Coopervision INC. | $386.26 | 2020-2025 | Onefit Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $339.13 | 2019-2020 | |
| Allergan, INC. | $279.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $270.08 | 2019-2023 | |
| Harrow Eye, LLC | $266.91 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $242.64 | 2019-2022 | |
| Abbvie INC. | $193.57 | 2023-2024 | Vuity, Alphagan P, Lumigan |
| Thea Pharma INC. | $181.80 | 2022-2025 | |
| Sight Sciences, INC. | $176.24 | 2019-2024 | Tearcare System, Omni Surgical System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $140.74 | 2019 | |
| Carl Zeiss Meditec, INC. | $117.24 | 2020 | |
| Biotissue Holdings INC. | $85.80 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $61.97 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $51.73 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $40.56 | 2019-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rosin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.